TY - JOUR
T1 - Targeting N-acetylglucosamine-bearing polymer-coated liposomes to vascular smooth muscle cells
AU - Ise, Mamiko
AU - Ise, Hirohiko
AU - Shiba, Yuji
AU - Kobayashi, Satoshi
AU - Goto, Mitsuaki
AU - Takahashi, Masafumi
AU - Akaike, Toshihiro
AU - Ikeda, Uichi
N1 - Funding Information:
This work was supported in part by a Grant-in-Aid for Scientific Research on Innovative Areas (No. 20200016) from the Ministry of Education, Science, Sports, Culture, and Technology of Japan. We are grateful to Dr. Nakagami from Osaka University for providing NF-κB decoy oligonucleotides.
PY - 2011/12
Y1 - 2011/12
N2 - The targeted delivery of anti-inflammatory agents has great therapeutic potential for treating restenosis following percutaneous coronary intervention. To develop a drug delivery system targeted to injured blood vessels, we examined whether N-acetylglucosamine (GlcNAc)-bearing polymer-coated liposomes (GlcNAc-Ls) are specifically taken up by vascular smooth muscle cells (VSMCs). Flow cytometric analysis revealed that GlcNAc-Ls were taken up by VSMCs in vitro. Furthermore, GlcNAc-Ls were intravenously administered to mice that had undergone wire-mediated vascular injury. GlcNAc-Ls markedly accumulated at the intramural site of the injured vessel walls but not at the contralateral (uninjured) vessel walls. These results demonstrated that GlcNAc-Ls can be specifically taken up by VSMCs both in vitro and in vivo. We propose a novel strategy of using GlcNAc-Ls that has potential for application in drug delivery targeted to injured blood vessels.
AB - The targeted delivery of anti-inflammatory agents has great therapeutic potential for treating restenosis following percutaneous coronary intervention. To develop a drug delivery system targeted to injured blood vessels, we examined whether N-acetylglucosamine (GlcNAc)-bearing polymer-coated liposomes (GlcNAc-Ls) are specifically taken up by vascular smooth muscle cells (VSMCs). Flow cytometric analysis revealed that GlcNAc-Ls were taken up by VSMCs in vitro. Furthermore, GlcNAc-Ls were intravenously administered to mice that had undergone wire-mediated vascular injury. GlcNAc-Ls markedly accumulated at the intramural site of the injured vessel walls but not at the contralateral (uninjured) vessel walls. These results demonstrated that GlcNAc-Ls can be specifically taken up by VSMCs both in vitro and in vivo. We propose a novel strategy of using GlcNAc-Ls that has potential for application in drug delivery targeted to injured blood vessels.
UR - http://www.scopus.com/inward/record.url?scp=84855254621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855254621&partnerID=8YFLogxK
U2 - 10.1007/s10047-011-0595-3
DO - 10.1007/s10047-011-0595-3
M3 - Article
C2 - 21809097
AN - SCOPUS:84855254621
SN - 1434-7229
VL - 14
SP - 301
EP - 309
JO - Journal of Artificial Organs
JF - Journal of Artificial Organs
IS - 4
ER -